These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-004475-12 Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancer bad-data
Ongoing, reported early 2005-003325-67 Estudio aleatorizado, multicéntrico, fase III, para estudiar la eficacia y seguridad de bevacizumab solo o en combinación con capecitabina y oxaliplatino, como terapia de mantenimiento, tras tratamien... not-yet-due
Ongoing 2006-000834-11 Estudio multicéntrico fase II, abierto, de tratamiento con cetuximab y capecitabina en primera línea de tratamiento en pacientes ancianos con un cáncer colorrectal metastático not-yet-due
Ongoing 2006-001880-42 Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de la combinación de cetuximab y quimioterapia (docetaxel, cisplatin, 5-fluorouracilo) como tratamien... not-yet-due
Not reported 2006-006363-24 An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer. 2010-03-30 due-trials
Ongoing 2006-007062-11 ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, NO RANDOMIZADO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CETUXIMAB (ERBITUX®) EN COMBINACIÓN CON OXALIPLATINO Y CAPECITABINA (XELOX) DURANTE 12 SEMANAS SEGUIDO D... not-yet-due
Completed, but no date 2008-001825-32 "Fase II Docetaxel-Oxiplatino-Capecitabina (DOX) a dosis ajustadas en pacientes con adenocarcinoma gástrico avanzado y estado general subóptimo" bad-data
Completed, but no date 2008-004688-20 Estudio de fase II con una combinación de Irinotecán, Capecitabina (Xeloda®) y Bevacizumab (Avastin®) en cáncer colorrectal metastático no pretratado bad-data
Ongoing, reported early 2008-006766-28 Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapia F... not-yet-due
Completed, but no date 2009-010192-24 Estudio fase II randomizado de Capecitabina + Bevacizumab versus Capecitabina + Oxaliplatino + Bevacizumab en combinación con radioterapia externa como tratamiento preoperatorio en pacientes con cánce... bad-data
Completed, but no date 2009-010833-27 Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y re... bad-data
Ongoing 2009-012562-31 Tratamiento selectivo en cáncer colorrectal: selección de capecitabina o 5-fluorouracilo para ser combinados con oxaliplatino o irinotecan como quimioterapia en combinación con bevacizumab en primera... not-yet-due
Completed, but no date 2009-016661-28 Estudio de fase II de panitumumab como agente único de primera línea en pacientes ancianos frágiles con cáncer colorrectal avanzado con KRAS no mutado bad-data
Ongoing, reported early 2009-017194-38 Estudio piloto fase II aleatorizado, multicentrico para evaluar la seguridad y eficacia del tratamiento de mFOLFOX-6 mas cetuximab frente a un tratamiento inicial con mFOLFOX-6 mas cetuximab (por 8 ci... not-yet-due
Completed, but no date, and reported results 2010-022599-30 ENSAYO fase IIb randomizado para evaluar la eficacia de Gemcitabina-Erlotinib vs Gemcitabina- Erlotinib-Capecitabina en pacientes con cáncer de páncreas metastásico. bad-data
Ongoing 2011-002384-16 A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma. not-yet-due
Completed, report not yet due 2012-000840-90 Randomized phase II study to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with KRAS wild-type metastatic c... 2018-11-04 not-yet-due
Completed, report not yet due 2012-000846-37 Phase III, randomized clinical trial to evaluate FOLFOX + bebacizumab versus FOLFOXIRI + bebacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and wi... 2018-11-30 not-yet-due
Not reported 2012-001955-38 Open label Phase II study of Folfiri + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinoteca... 2016-07-30 due-trials
Completed, but no date 2013-000236-94 Phase II study of Regorafenib as a single agent for first-line treatment of patients with metastatic colorectal cancer (MCRC) who are fragile and/or not candidates for polychemotherapy bad-data
Completed, but no date 2014-000703-26 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab. bad-data
Exempt 2014-005350-19 A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma not-yet-due
Completed, report not yet due 2016-000640-34 A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients 2018-09-24 not-yet-due
Completed, report not yet due 2016-001508-45 Phase II clinical trial to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms 2018-12-11 not-yet-due
Ongoing 2016-004076-21 Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by ... not-yet-due
Ongoing 2018-000347-60 Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panit... not-yet-due